Entrada Therapeutics’ experimental next-generation drug for Duchenne muscular dystrophy (DMD) failed to meet expectations in an early-stage clinical trial, casting doubt on the company’s standing in a highly competitive treatment landscape.
DMD is a severe genetic disorder characterized by the absence of dystrophin, a protein essential for muscle function. Exon-skipping therapies aim to enable patients with specific genetic mutations to produce a shortened but functional version of the protein.
The first exon-skipping drug, developed by Sarepta Therapeutics, received FDA approval in 2016 despite producing only marginal improvements in dystrophin levels. The approval was heavily influenced by advocacy from patient groups and families affected by the disease.
Since then, advancements in molecular design have allowed researchers to enhance these therapies, significantly increasing dystrophin production in muscle tissues. However, Entrada’s latest candidate did not demonstrate the expected efficacy in early testing, leaving its future in the DMD treatment space uncertain.
Related articles
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...
Kyle Diamantas Named Acting FDA Commissioner Amid Biotech Sector Optimism
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their...
Gene Therapy Viruses Linked to Rare Tumor in Young Patient: FDA Commissioner Resigns Amid Safety Concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get st...
FDA Commissioner Marty Makary Resigns Amid Leadership Controversy; Eli Lilly Weight Loss Drug Trial Results Released
Good morning, everyone, and how are you today? The middle of the week has finally arrived, and you should congratulate yourselves for making it this f...